H
The startup develops cancer vaccines that activate anti-cancer T-cell immune responses targeting neo-antigens from genetic frameshift mutations associated with microsatellite instability (MSI). This approach aims to improve the quality of life for cancer patients by addressing their unmet medical needs through personalized immunotherapy.
Oslo, Norway
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops cancer vaccines that activate anti-cancer T-cell immune responses targeting neo-antigens from genetic frameshift mutations associated with microsatellite instability (MSI). This approach aims to improve the quality of life for cancer patients by addressing their unmet medical needs through personalized immunotherapy.